(Q33628162)

28 July 2017

title

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study (English)

1 reference

28 July 2017

main subject

hepatic encephalopathy

1 reference

1 reference

Yong Han Paik

1

1 reference

28 July 2017

Kwan Sik Lee

2

1 reference

28 July 2017

Kwang Hyub Han

3

1 reference

28 July 2017

Kun Hoon Song

4

1 reference

28 July 2017

Myoung Hwan Kim

5

1 reference

28 July 2017

Byung Soo Moon

6

1 reference

28 July 2017

Sang Hoon Ahn

7

1 reference

28 July 2017

Se Joon Lee

8

1 reference

28 July 2017

Hyo Jin Park

9

1 reference

28 July 2017

Dong Ki Lee

10

1 reference

28 July 2017

Chae Yoon Chon

11

1 reference

28 July 2017

Sang In Lee

12

1 reference

28 July 2017

Young Myoung Moon

13

1 reference

28 July 2017

language of work or name

1 reference

1 June 2005

1 reference

28 July 2017

published in

Yonsei Medical Journal

1 reference

28 July 2017

volume

46

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

399-407

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

28 July 2017

copyright license

start time

1 January 2005

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Epidemiology of alcoholic liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Hepatic encephalopathy: a review.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Management of hepatic encephalopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Effect of race on outcome of orthotopic liver transplantation: a cohort study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Lactulose, disaccharides and colonic flora. Clinical consequences

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Rolling review: the treatment of major complications of cirrhosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

A controlled clinical trial of lactulose in hepatic encephalopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Control of chronic portal-systemic encephalopathy by lactulose

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Metronidazole pharmacokinetics in patients with hepatic encephalopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Treatment of hepatic encephalopathy with non-absorbable antibiotics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

The relation of the trail making test to organic brain damage.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

30 October 2018

Hepatic Encephalopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815818

Small bowel bacterial overgrowth in patients with alcoholic cirrhosis

30 October 2018

1 reference

12 December 2020

Challenges of designing hepatic encephalopathy treatment trials

1 reference

12 December 2020

Hypernatremia in hepatic failure

1 reference

12 December 2020

Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis

1 reference

12 December 2020

Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy

1 reference

12 December 2020

Treatment of hepatic encephalopathy

1 reference

12 December 2020

A non-absorbable rifamycin for treatment of hepatic encephalopathy

1 reference

12 December 2020

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

1 reference

12 December 2020

Rifaximine versus neomycin in the treatment of portosystemic encephalopathy

1 reference

12 December 2020

10.3349/YMJ.2005.46.3.399

Identifiers

DOI

1 reference

28 July 2017

1 reference

28 July 2017

1 reference